New Issue: Orbital Catastrophe Ahead? Read Now

Extra Gene Makes Mice Manic

A common mood-stabilizing drug, valproate, is found to control manic-like behavior induced in mice with an extra copy of a gene called SHANK3

Join Our Community of Science Lovers!

Duplication of a single gene — and too much of the corresponding protein in brain cells — causes mice to have seizures and display manic-like behavior, a study has found. But a widely used drug reversed the symptoms, suggesting that it could also help some people with hyperactivity who do not respond to common treatments.

Smooth functioning at the synapses, the junctions between brain cells, is crucial to functions that control everything from social etiquette to everyday decision-making. It is increasingly thought that some neuropsychiatric disorders are caused by function of the synapses going awry, and indeed researchers have found that neuropsychiatric conditions such as schizophrenia and autism can sometimes be traced to missing or mutated copies of SHANK3, a gene that encodes one of the 'architectural' proteins that help to ensure that messages are relayed properly between cells. Some people with attention deficit hyperactivity disorder (ADHD), Asperger's syndrome or schizophrenia have an extra copy of a wider region of DNA that contains SHANK3.

To explore the role of SHANK3, Huda Zoghbi, a neurogeneticist at Baylor College of Medicine in Houston, Texas, and her colleagues created mice with duplicate copies of the gene. “The mouse was remarkably hyperactive, running around like mad,” says Zoghbi. But the animals did not respond to stimulant medications typically used to treat ADHD. Instead, their hyperactivity grew much worse. “That’s when we knew this was not typical ADHD,” says Zoghbi. The study is published today in Nature.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


The paper is a “really good example of the importance of gene dosage”, says Thomas Insel, director of the US National Institute of Mental Health in Bethesda, Maryland. “It matters a lot whether you have no copies, one copy, two copies” or more of a given gene, he says.

Human parallels
In addition to hyperactivity, the mice displayed a combination of mania-like behaviors and seizures, which are indicative of a disorder called hyperkinesia. When the researchers sifted through clinical databases, they found records of two people whose psychiatric profiles resembled those of the mice, and who also carried a duplication of SHANK3. One had bipolar disorder and epilepsy; the other had seizures and ADHD characterized by hyperactivity, poor attention and compulsive behavior. Like the mice, this person had not responded well to amphetamines used to treat ADHD.

After trying various treatments, the researchers gave the mice valproate, an anticonvulsant and mood-stabilizing drug commonly used to treat bipolar disorder and epilepsy. Remarkably, the drug reversed the psychiatric effects. The results suggest that excess SHANK3 protein drives a psychiatric syndrome that can be treated effectively.

Joe Gleeson, a pediatric neurologist and geneticist at the University of California, San Diego, says that the study is “one of the first to explore, in a comprehensive way” the importance of gene dosage in mouse neurological disorders. He says that the paper addresses the underpinnings of these disorders on all fronts, from psychopharmacology to proteomics and human genomics, and notes that “the results are all in alignment”.

This article is reproduced with permission from the magazine Nature. The article was first published on October 23, 2013.

First published in 1869, Nature is the world's leading multidisciplinary science journal. Nature publishes the finest peer-reviewed research that drives ground-breaking discovery, and is read by thought-leaders and decision-makers around the world.

More by Nature magazine

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe